SIGA,
Press Release Source: SIGA Technologies, Inc.
SIGA Adds Vice President of Clinical and Regulatory Affairs to Management Team
Wednesday May 7, 8:00 am ET
NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced the appointment of Seane Jones as the new Vice President of Clinical and Regulatory Affairs, effective April 29, 2008. Ms. Jones will direct the execution of the company's ongoing regulatory strategy and will have responsibility for all regulatory submissions with respect to SIGA’s product candidates.
ADVERTISEMENT
Ms. Jones is an accomplished regulatory affairs professional with experience bringing drug candidates through the regulatory process in the United States and internationally, including in the European Union. Prior to joining SIGA, Ms. Jones was with Alcon Laboratories, where she served as Director of Regulatory Affairs, ENT and Generics. While at Alcon Laboratories, Inc., she managed the FDA filing of 8 Investigational New Drug Applications and 5 New Drug Applications, 4 of which went on to receive NDA approval. Prior to this, she held roles at Geneva Pharmaceuticals, Inc., Steris Laboratories and Pathogenesis Corp.
Dr. Eric A. Rose, SIGA’s Chief Executive Officer, commented, “We are delighted to have Seane as a member of SIGA’s management team and bring to bear her considerable experience in the development and approval processes associated with small molecule compounds. Her successful track record seeing drugs through the regulatory approval process, both in the U.S. and abroad, makes her a valuable asset as we enter the final stages in the approval of ST-246, our small molecule orthopoxvirus inhibitor intended for the treatment of smallpox and other orthopoxvirus diseases. Seane’s knowledge and insight will also help pave the way for several of our other programs that are at an earlier stage in the development pipeline.”
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA’s Web site at siga.com. |
